List of Jevtana Kit drug patents

Jevtana Kit is owned by Sanofi Aventis Us.

Jevtana Kit contains Cabazitaxel.

Jevtana Kit has a total of 6 drug patents out of which 0 drug patents have expired.

Jevtana Kit was authorised for market use on 17 June, 2010.

Jevtana Kit is available in solution;intravenous dosage forms.

Jevtana Kit can be used as increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist, increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist, increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist.

The generics of Jevtana Kit are possible to be released after 27 April, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7241907 SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation
Dec, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7241907

(Pediatric)

SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation
Jun, 2026

(3 years from now)

US10583110 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(7 years from now)

US10716777 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(7 years from now)

US8927592 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(7 years from now)

US8927592

(Pediatric)

SANOFI AVENTIS US Antitumoral use of cabazitaxel
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M Dec 18, 2023

Drugs and Companies using CABAZITAXEL ingredient

Market Authorisation Date: 17 June, 2010

Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist; Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of JEVTANA KIT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in